<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800097</url>
  </required_header>
  <id_info>
    <org_study_id>ModaA001</org_study_id>
    <nct_id>NCT01800097</nct_id>
  </id_info>
  <brief_title>Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent</brief_title>
  <official_title>Treatment of Post Stroke Fatigue With Modafinil, Effect on Rehabilitation, Fatigue and Bonemass Index</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an investigator initiated placebo controlled double blinded trial. The
      hypothesis is that treatment with modafinil positively will affect behavioural and cognitive
      rehabilitation after stroke, causing the treatment group to experience decreased fatigue,
      increased endurance, improved skills of sustaining attention and faster reaction times. The
      cognitive rehabilitation will show in increased muscle mass, decreased osteoporosis and
      better physical performances due to a higher level of physical activity.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Multidimensional Fatigue Inventory (MFI- 20)</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MFI-20</measure>
    <time_frame>1 month</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MFI-20</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue severity scale (FSS)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSS</measure>
    <time_frame>1 month</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FSS</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in bone mineral density and musclemass from baseline to 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>DXA-scans. (dual energy x-ray absorptiometry)</description>
  </other_outcome>
  <other_outcome>
    <measure>Reactiontime</measure>
    <time_frame>1 month</time_frame>
    <description>A special designed computerprogramme will be used to measure the patients reactiontime.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Specific Quality Of Life (SSQOL)</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Barthel Index</measure>
    <time_frame>3 months</time_frame>
    <description>score</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Ranking Scale</measure>
    <time_frame>3 months</time_frame>
    <description>score</description>
  </other_outcome>
  <other_outcome>
    <measure>Multidimensional Depression Inventory</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in &quot;Time up and go&quot; and &quot;chair to stand test&quot; from baseline</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive performance, Montreal Cognitive Assessment(MOCA)</measure>
    <time_frame>3 months</time_frame>
    <description>test</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in bone mineral density and musclemass from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>DXA-scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Reactiontime</measure>
    <time_frame>3 months</time_frame>
    <description>A special designed computerprogramme will be used to measure the patients reactiontime.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reactiontime</measure>
    <time_frame>6 months</time_frame>
    <description>A special designed computerprogramme will be used to measure the patients reactiontime.</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Specific Quality Of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Barthel Index</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Modified Ranking Scale</measure>
    <time_frame>6 months</time_frame>
    <description>score</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in &quot;Time up and go&quot; and &quot;chair to stand test&quot; from baseline</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Multidimensional Depression Inventory</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive performance, Montreal Cognitive Assessment(MOCA)</measure>
    <time_frame>6 months</time_frame>
    <description>test</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke Specific Quality Of Life (SSQOL)</measure>
    <time_frame>1 month</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Barthel Index</measure>
    <time_frame>1 month</time_frame>
    <description>score</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Ranking Scale</measure>
    <time_frame>1 month</time_frame>
    <description>score</description>
  </other_outcome>
  <other_outcome>
    <measure>Multidimensional Depression Inventory</measure>
    <time_frame>1 month</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in &quot;Time up and go&quot; and &quot;chair to stand test&quot; from baseline</measure>
    <time_frame>1 month</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Cognitive performance, Montreal Cognitive Assessment(MOCA)</measure>
    <time_frame>1 month</time_frame>
    <description>test</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Stroke</condition>
  <condition>Post Stroke Fatigue</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Modafinil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Modafinil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>modafinil</intervention_name>
    <description>Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months</description>
    <arm_group_label>Modafinil</arm_group_label>
    <other_name>modiodal, provigil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age and stroke within 14 days

          -  Modified Rankin Scale 3 or under and Barthel 85 or over before stroke

          -  Person that can understand instruction and do tests and questionnaires on their own or
             with support

          -  has given informed consent

          -  MFI-20 score of 12 or more

          -  Infertile person or fertile women tested negative of pregnancy and using safe
             anticonception

        Exclusion Criteria:

          -  Dementia or other neuropsychiatric disease making the person incapable of
             understanding instructions

          -  Other disease with fatigue as a known symptom

          -  stroke induced by trauma, infection or surgical procedure

          -  former drug abuse

          -  known contraindication to treatment with modafinil

          -  known active malignancy, benign intracranial tumor, subdural or epidural bleeding

          -  kidneydysfunction with creatinin more than 265 micromol/L or liver disease with ASAT
             (aspartate aminotransferase) elevated to more than 70 U/L for women or 100 U/L for
             men.

          -  allergy to project treatment

          -  use of benzodiazepin or antiepileptic drugs in a fixed dose. Sleeping pills not
             included.

          -  Patients threaded with ciclosporin or anti HIV medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karsten Overgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Neurology, Herlev Hospital,</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Karsten Overgaard</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>fatigue</keyword>
  <keyword>modafinil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Wakefulness-Promoting Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

